Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: non-small-cell lung cancer complicated by diabetes mellitus (DM) who developed BP while receiving DPP-4is and ICIs
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
We herein report two patients with non-small-cell lung cancer complicated by diabetes mellitus (DM) who developed BP while receiving DPP-4is and ICIs. The clinical course of these patients suggests that the combination of DPP-4is and ICIs may carry a potential risk of BP development.
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are shown to be associated with the development of bullous pemphigoid (BP).
APA
Nakashima K, Demura Y, et al. (2025). Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature.. Internal medicine (Tokyo, Japan), 64(20), 2995-2999. https://doi.org/10.2169/internalmedicine.5090-24
MLA
Nakashima K, et al.. "Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature.." Internal medicine (Tokyo, Japan), vol. 64, no. 20, 2025, pp. 2995-2999.
PMID
40189295 ↗
Abstract 한글 요약
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are shown to be associated with the development of bullous pemphigoid (BP). Immune checkpoint inhibitors (ICIs) can lead to BP development. Therefore, the combination of DPP-4is and ICIs may predispose an individual to developing BP; however, few reports have focused on this issue. We herein report two patients with non-small-cell lung cancer complicated by diabetes mellitus (DM) who developed BP while receiving DPP-4is and ICIs. The clinical course of these patients suggests that the combination of DPP-4is and ICIs may carry a potential risk of BP development.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Non-Small-Cell Lung
- Diabetes Mellitus
- Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Immune Checkpoint Inhibitors
- Lung Neoplasms
- Pemphigoid
- Bullous
- DPP-4 inhibitor
- bullous pemphigoid
- dipeptidyl peptidase-4 (DPP-4)
- immune checkpoint inhibitor (ICI)
- immune-related adverse event (irAE)
- non-small-cell lung cancer (NSCLC)
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.